- Elicio Therapeutics to Present at the Oppenheimer 34th Annual Healthcare Life Sciences Conference
- Elicio Therapeutics Announces Publication of Preclinical Data Demonstrating TCR-T Cell Therapy in Combination with Lymph Node-Targeted Amphiphile-Immunotherapy Enhanced Anti-Tumor Function and Eradicated Solid Tumors
- Elicio Therapeutics to Present ELI-002 7P (AMPLIFY-7P) Trial in Progress Poster on Phase 1/2 Study of Lymph Node-Targeted Vaccine at ASCO GI Symposium
- Elicio Therapeutics to Present at the B. Riley Securities 4th Annual Oncology Conference
- Elicio Therapeutics Announces First Patient Dosed in Randomized Phase 2 Pancreatic Cancer Study
- Nature Medicine Publishes Updated Preliminary Phase 1 Data From Elicio Therapeutic’s AMPLIFY-201 Phase 1 Solid Tumor Study of ELI-002
- Elicio Therapeutics Announces $7.0 Million Private Placement Financing
- Elicio Therapeutics to Present at the H.C. Wainwright 4th Annual Precision Oncology Virtual Conference
- Elicio Therapeutics Reports Third Quarter 2023 Financial Results and Provides Corporate Updates
- Elicio Therapeutics Presents Updated Preliminary Immunogenicity Data from the Ongoing Phase 1 Study of ELI-002 and New Preclinical Data on ELI-007 and ELI-008 at the Society for Immunotherapy of Cancer (SITC 2023) Annual Meeting
More ▼
Key statistics
On Thursday, Elicio Therapeutics Inc (ELTX:NMQ) closed at 9.00, 204.05% above the 52 week low of 2.96 set on Feb 07, 2024.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 9.00 |
---|---|
High | 9.00 |
Low | 8.84 |
Bid | 6.50 |
Offer | 10.00 |
Previous close | 8.85 |
Average volume | 36.69k |
---|---|
Shares outstanding | 10.24m |
Free float | 5.62m |
P/E (TTM) | -- |
Market cap | 90.58m USD |
EPS (TTM) | -8.81 USD |
Data delayed at least 15 minutes, as of May 02 2024 21:00 BST.
More ▼